<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711048</url>
  </required_header>
  <id_info>
    <org_study_id>D9127C00001</org_study_id>
    <secondary_id>2008-000313-30</secondary_id>
    <nct_id>NCT00711048</nct_id>
  </id_info>
  <brief_title>Esophageal Hypersensitivity Study in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Two Centre, Double-blind, Randomized, Cross-over Study to Evaluate AZD1386 in Single Doses of 30 mg and 95 mg Compared to Placebo in a Multimodal Experimental Pain Model on Esophageal Sensitivity and Development of Sensitization in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare sensitivity and sensitization of visceral pain in the
      esophagus using different pain stimuli
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS scale and clock</measure>
    <time_frame>Several occasions during the study days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS scale and pressure, VAS scale and current, VAS scale and acid volume</measure>
    <time_frame>Several occasions during the study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables</measure>
    <time_frame>Several occasions during the study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety variables (adverse events, blood pressure, safety lab, ECG and body temperature)</measure>
    <time_frame>Several occasions during the study days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Pain</condition>
  <condition>Esophageal Sensitivity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg, oral, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>95 mg, oral, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral solution, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1386</intervention_name>
    <description>oral, single dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral solution, single dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written consent

          -  Clinically normal physical findings

          -  Sensitization potential

        Exclusion Criteria:

          -  Clinically significant illness within 2 weeks prior to the first dose of
             investigational product

          -  History of clinically significant disease

          -  Use of prescribed medication during the 2 weeks before administration of the first
             dose of investigational product
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Sundin</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, MÃ¶lndal, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Funch-Jensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital, Dept of Surgical Gastroenterology, Aarhus, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2008</study_first_submitted>
  <study_first_submitted_qc>July 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2008</study_first_posted>
  <last_update_submitted>August 27, 2009</last_update_submitted>
  <last_update_submitted_qc>August 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mark Berner Hansen, MD, PhD, Acting Medical Science Director, Emerging Products CV/GI</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>GERD</keyword>
  <keyword>healthy volunteer</keyword>
  <keyword>esophagus</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

